Clinical Trial

Disease: B-cell Non-Hodgkin Lymphoma, NHL, (NCT05169489)

Disease info:

B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. 

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that's used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. Non-Hodgkin lymphoma is one of the most common cancers in the United States, accounting for about 4% of all cancers. 


B-cell NHL is the most common type of non-Hodgkin lymphoma. NHL accounts for about 4% of all cancers in the U.S. The American Cancer Society estimates 80,550 people will be diagnosed with NHL in 2023.
Official title:
A Phase 1/2 Study of bbT369, a Dual Targeting CAR T Cell Drug Product With a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)


Name: Anna Truppel-Hartmann, MD

Phone: Clinical Trials Office 617-798-4270



United States, California

Stanford Cancer Institute, Stanford, California, United States, 94305


United States, Colorado

Colorado Blood Cancer Institute, Denver, Colorado, United States, 80218


United States, Florida

Moffitt Cancer Center, Tampa, Florida, United States, 33612


United States, Tennessee

Sarah Cannon, Nashville, Tennessee, United States, 37203

Study start:
Jan. 24, 2022
50 participants
Gene editing method:
Type of edit:
Gene knock-out
Delivery method:
Transfection with mRNA - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting


bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene.

Last updated: Apr. 20, 2024
Search CRISPR Medicine